menu
    • menu
    [{"orgOrder":0,"company":"A&G Pharmaceutical","sponsor":"University of Maryland Greenebaum Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"AG-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"A&G Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A&G Pharmaceutical \/ University of Maryland Greenebaum Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"A&G Pharmaceutical \/ University of Maryland Greenebaum Cancer Center"},{"orgOrder":0,"company":"A&G Pharmaceutical","sponsor":"Precision Antibody","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"A&G Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A&G Pharmaceutical \/ Precision Antibody","highestDevelopmentStatusID":"4","companyTruncated":"A&G Pharmaceutical \/ Precision Antibody"}]

    Find Clinical Drug Pipeline Developments & Deals by A&G Pharmaceutical

    Menu

    A&G Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            A&G Pharmaceutical

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            A&G Pharmaceutical

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG-01,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of Maryland Greenebaum Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            November 28, 2022

                            Lead Product(s) : AG-01,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of Maryland Greenebaum Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            A&G Pharmaceutical

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            A&G Pharmaceutical

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Precision Antibody

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Identification of An Internalizing Cancer Target for Novel Antibody Drug Conjugate by A&G Pharmaceutical and P...

                            Details : To characterize an internalizing monoclonal antibody, identify its target by mass spectrometry as PTGFRN and shows its efficacy as ADC in vitro and in vivo, for several cancer types including head and neck cancers and spindle cell carcinoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 06, 2021

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Precision Antibody

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth